Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C J Jorgensen, Trang D Trinh, Evan J Zasowski, Abdalhamid M Lagnf, Samuel Simon, Sahil Bhatia, Sarah Melvin, Molly E. Steed, Natalie A. Finch, Taylor Morrisette, Sandy Estrada, Joshua Rosenberg, Susan L. Davis, Michael J. Rybak
Abstract
Our objective was to describe the prescribing practices, clinical characteristics, and outcomes of patients treated with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) Gram-negative infections. This was a multicenter, retrospective, cohort study at eight U.S. medical centers (2015 to 2019). Inclusion criteria were age ≥18 years and receipt of C/T (≥72 hours) for suspected or confirmed MDR Gram-negative infection. The primary efficacy outcome, evaluated among patients with MDR Pseudomonas aeruginosa infections, was composite clinical failure, namely, 30-day all-cause mortality, 30-day recurrence, and/or failure to resolve or improve infection signs or symptoms after C/T treatment.